The future for treating Creutzfeldt–Jakob disease

Bibliography

• Gibbs CJ, Gajdusek DC, Asher DM, et al. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 1968;161:388-9
   PubMed Web of Science ®Google Scholar
• Alpers MP. The epidemiology of kuru: monitoring the epidemic from its peak to its end. Philos Trans R Soc Lond B Biol Sci 2008;363:3707-13
   PubMed Web of Science ®Google Scholar
• Detwiler LA, Baylis M. The epidemiology of scrapie. Rev Sci Tech 2003;22:121-43
   PubMed Web of Science ®Google Scholar
• Brown P, Cathala F, Gajdusek DC. Creutzfeldt-Jakob disease in France: III. Epidemiological study of 170 patients dying during the decade 1968-1977. Ann Neurol 1979;6:438-46
   Google Scholar
• Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-88
   PubMed Web of Science ®Google Scholar
• Will RG, Alperovitch A, Poser S, et al. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU collaborative study group for CJD. Ann Neurol 1998;43:763-7
   PubMedGoogle Scholar
• Ladogana A, Puopolo M, Croes EA, et al. Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada. Neurology 2005;64:1586-91
   PubMed Web of Science ®Google Scholar
• Poggiolini I, Saverioni D, Parchi P. Prion protein misfolding, strains, and neurotoxicity: an update from studies on Mammalian prions. Int J Cell Biol 2013;2013:910314
   PubMedGoogle Scholar
• Brown P, Brandel JP, Sato T, et al. Creutzfeldt-Jakob disease, final assessment. Emerg Infect Dis 2012;18:901-7
   PubMed Web of Science ®Google Scholar
• Ward HJ, Everington D, Cousens SN, et al. Risk factors for variant Creutzfeldt-Jakob disease: a case-control study. Ann Neurol 2006;59:111-20
   PubMed Web of Science ®Google Scholar
• Graziano S, Pocchiari M. Management and prevention of human prion diseases. Curr Neurol Neurosci Rep 2009;9:423-9
   Google Scholar
• Pocchiari M, Puopolo M, Croes EA, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004;127:2348-59
   PubMed Web of Science ®Google Scholar
• Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009;132:2659-68
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Shu H, Haman A, et al. Rapidly progressive dementia. Ann Neurol 2008;64:97-108
   PubMed Web of Science ®Google Scholar
• Collins SJ, Sanchez-Juan P, Masters CL, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. Brain 2006;129:2278-87
   PubMed Web of Science ®Google Scholar
• Heath CA, Cooper SA, Murray K, et al. Diagnosing variant Creutzfeldt-Jakob disease: a retrospective analysis of the first 150 cases in the UK. J Neurol Neurosurg Psychiatry 2011;82:646-51
   PubMed Web of Science ®Google Scholar
• Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006;67:637-43
   PubMed Web of Science ®Google Scholar
• Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-15
   PubMed Web of Science ®Google Scholar
• Green AJ, Thompson EJ, Stewart GE, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2001;70:744-8
   PubMed Web of Science ®Google Scholar
• Summers DM, Collie DA, Zeidler M, Will RG. The pulvinar sign in variant Creutzfeldt-Jakob disease. Arch Neurol 2004;61:446-7
   Google Scholar
• Chitravas N, Jung RS, Kofskey DM, et al. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol 2011;70:437-44
   PubMed Web of Science ®Google Scholar
• Kovács GG, Puopolo M, Ladogana A, et al. Genetic prion disease: the EUROCJD experience. Hum Genet 2005;118:166-74
   PubMed Web of Science ®Google Scholar
• Pocchiari M, Poleggi A, Puopolo M, et al. Age at death of Creutzfeldt-Jakob disease in subsequent family generation carrying the E200K mutation of the prion protein gene. PLoS One 2013;8:e60376
   Google Scholar
• Ladogana A, Puopolo M, Poleggi A, et al. High incidence of genetic human transmissible spongiform encephalopathies in Italy. Neurology 2005;64:1592-7
   PubMed Web of Science ®Google Scholar
• Properzi F, Pocchiari M. Identification of misfolded proteins in body fluids for the diagnosis of prion diseases. Int J Cell Biol 2013;2013:839329
   Google Scholar
• Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 2011;17:175-8
   PubMed Web of Science ®Google Scholar
• McGuire LI, Peden AH, Orrú CD, et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2012;72:278-85
   PubMed Web of Science ®Google Scholar
• Orrú CD, Bongianni M, Tonoli G, et al. A test for Creutzfeldt-Jakob disease using nasal brushings. N Engl J Med 2014;371:519-29
   PubMed Web of Science ®Google Scholar
• Moda F, Gambetti P, Notari S, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med 2014;371:530-9
   PubMed Web of Science ®Google Scholar
• Jackson GS, Burk-Rafel J, Edgeworth JA, et al. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. JAMA Neurol 2014;71:421-8
   Web of Science ®Google Scholar
• Stewart LA, Rydzewska LHM, Keogh GF, et al. Systematic review of therapeutic interventions in human prion disease. Neurology 2008;70:1272-81
   PubMed Web of Science ®Google Scholar
• Sim VL, Caughey B. Recent advances in prion chemotherapeutics. Infect Disord Drug Targets 2009;9:81-91
   Google Scholar
• Zerr I. Therapeutic trials in human transmissible spongiform encephalopathies: recent advances and problems to address. Infect Disord Drug Targets 2009;9:92-9
   PubMedGoogle Scholar
• Appleby BS, Lyketsos CG. Rapidly progressive dementias and the treatment of human prion diseases. Expert Opin Pharmacother 2011;12:1-12
   PubMed Web of Science ®Google Scholar
• Sim VL. Prion disease: chemotherapeutic strategies. Infect Disord Drug Targets 2012;12:144-60
   PubMedGoogle Scholar
• Forloni G, Artuso V, Roiter I, et al. Therapy in prion diseases. Curr Top Med Chem 2013;13:2465-76
   PubMed Web of Science ®Google Scholar
• Roettger Y, Du Y, Bacher M, et al. Immunotherapy in prion disease. Nat Rev Neurol 2013;9:98-105
   PubMed Web of Science ®Google Scholar
• Newman PK, Todd NV, Scoones D, et al. Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate. J Neurol Neurosurg Psychiatry 2014;85:921-4
   PubMed Web of Science ®Google Scholar
• Braham J. Jakob-Creutzfeldt disease: treatment by amantadine. Br Med J 1971;4:212-13
   PubMedGoogle Scholar
• Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantadine. A report of two cases. J Neurol Neurosurg Psychiatry 1973;36:581-4
   PubMed Web of Science ®Google Scholar
• Braham J. Amantadine in the treatment of Creutzfeldt-Jakob disease. Arch Neurol 1984;41:585-6
   PubMedGoogle Scholar
• Terzano MG, Montanari E, Calzetti S, et al. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol 1983;40:555-9
   PubMedGoogle Scholar
• Neri G, Figa-Talamanca L, Di Battista GC, et al. Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution. Riv Neurobiol 1984;30:47-56
   PubMedGoogle Scholar
• Kimberlin RH, Walker CA. Antiviral compound effective against experimental scrapie. Lancet 1979;2:591-2
   PubMedGoogle Scholar
• Tateishi J. Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice. J Neurol Neurosurg Psychiatry 1981;44:723-4
   Google Scholar
• David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet 1984;1:512-13
   PubMed Web of Science ®Google Scholar
• Newman PK. Acyclovir in Creutzfeldt-Jakob disease. Lancet 1984;1:793
   PubMed Web of Science ®Google Scholar
• Furlow TWJ, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine. Lancet 1982;2:564-5
   PubMedGoogle Scholar
• Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. Br Med J 1980;280:902
   PubMedGoogle Scholar
• Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62:714-18
   PubMed Web of Science ®Google Scholar
• Perovic S, Pergande G, Ushijima H, et al. Flupirtine partially prevents neuronal injury induced by prion protein fragment and lead acetate. Neurodegeneration 1995;4:369-74
   PubMedGoogle Scholar
• Perovic S, Schroder HC, Pergande G, et al. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997;147:518-24
   PubMed Web of Science ®Google Scholar
• Perovic S, Bohm M, Meesters E, et al. Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer’s and prion diseases. Mech Ageing Dev 1998;101:1-19
   PubMed Web of Science ®Google Scholar
• Doh-ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000;74:4894-7
   PubMed Web of Science ®Google Scholar
• Korth C, May BCH, Cohen FE, et al. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-41
   PubMed Web of Science ®Google Scholar
• Bertrand A, Martinez-Almoyna L, De Broucker T. Hereditary Creutzfeldt-Jakob disease caused by a mutation at codon 200. Rev Neurol 2005;161:351-4
   PubMedGoogle Scholar
• Martinez-Lage JF, Rabano A, Bermejo J, et al. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 2005;64:542-5
   PubMed Web of Science ®Google Scholar
• Scoazec JY, Krolak-Salmon P, et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol 2003;53:546-7
   PubMed Web of Science ®Google Scholar
• Benito-Leon J. Combined quinacrine and chlorpromazine therapy in fatal familial insomnia. Clin Neuropharmacol 2004;27:201-3
   PubMed Web of Science ®Google Scholar
• Josefson D. Drugs for malaria and psychosis may offer hope to people with CJD. BMJ 2001;323:416
   Google Scholar
• Kobayashi Y, Hirata K, Tanaka H, Yamada T. Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft - an EEG evaluation. Rinsho Shinkeigaku 2003;43:403-8
   PubMedGoogle Scholar
• Nakajima M, Yamada T, Kusuhara T, et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2004;17:158-63
   PubMed Web of Science ®Google Scholar
• Satoh K, Shirabe S, Eguchi K, et al. Toxicity of quinacrine can be reduced by co-administration of p-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Mol Neurobiol 2004;24:873-5
   PubMed Web of Science ®Google Scholar
• Haik S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004;63:2413-15
   PubMed Web of Science ®Google Scholar
• Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009;8:334-44
   PubMed Web of Science ®Google Scholar
• Geschwind MD, Kuo AL, Wong KS, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 2013;81:2015-23
   PubMed Web of Science ®Google Scholar
• Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002;52:503-6
   PubMed Web of Science ®Google Scholar
• Barret A, Tagliavini F, Forloni G, et al. Evaluation of quinacrine treatment for prion diseases. J Virol 2003;77:8462-9
   PubMed Web of Science ®Google Scholar
• Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004;78:4999-5006
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S, Ahn M, Lessard P, et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009;5:e1000673
   PubMed Web of Science ®Google Scholar
• Tagliavini F, Forloni G, Colombo L, et al. Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(Sc) in vitro. J Mol Biol 2000;300:1309-22
   PubMed Web of Science ®Google Scholar
• Forloni G, Iussich S, Awan T, et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci USA 2002;99:10849-54
   PubMed Web of Science ®Google Scholar
• De Luigi A, Colombo L, Diomede L, et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One 2008;3:e1888
   PubMed Web of Science ®Google Scholar
• Tagliavini F. Prion therapy: tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease. Alzheimers Dement 2008;4(Suppl):T149-50
   Google Scholar
• Ponto C, Zerr I. Prionerkrankungen-welche Rolle spielen sie heute? InFo Neurologie Psychiatrie 2013;15:2-8
   Google Scholar
• Haik S, Marcon G, Mallet A, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:150-8
   PubMed Web of Science ®Google Scholar
• Todd NV, Morrow J, Doh-ura K, et al. Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 2005;50:394-6
   PubMed Web of Science ®Google Scholar
• Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Intraventricular infusion of pentosan polysulfate as an immediately applicable treatment for prion diseases [abstract No. 0-07]. International Congress on New Perspectives for Prion Therapeutics Meeting; 1 – 3 December 2002; Paris
   Google Scholar
• Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984;65:1325-30
   PubMed Web of Science ®Google Scholar
• Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992;73:661-5
   PubMed Web of Science ®Google Scholar
• Shirabe S, Satoh K, Eguchi K, et al. Effect of oral administration of pentosan polysulfate for patients with Creutzfeldt-Jakob disease (CJD) and new design for low molecular-weight of pentosan polysulfate. In: Kitamoto T, editor. Prions, food and drug safety. Springer-Verlag; Tokyo: 2005. p. 269-70
   Google Scholar
• Dealler S, Rainov NG. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. IDrugs 2003;6:470-8
   PubMedGoogle Scholar
• Rainov NG, Tsuboi Y, Krolak-Salmon P, et al. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Expert Opin Biol Ther 2007;7:713-26
   PubMed Web of Science ®Google Scholar
• Bone I, Belton L, Walker AS, Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 2008;15:458-64
   PubMed Web of Science ®Google Scholar
• Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009;29:632-6
   PubMed Web of Science ®Google Scholar
• Paterson RW, Torres-Chae CC, Kuo AL, et al. Differential diagnosis of Jakob- Creutzfeldt disease. Arch Neurol 2012;24:1-5
   Google Scholar
• Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006;129:2241-65
   PubMed Web of Science ®Google Scholar
• Brazier MW, Wall VA, Brazier BW, et al. Therapeutic interventions ameliorating prion disease. Expert Rev Anti Infect Ther 2009;7:83-105
   PubMed Web of Science ®Google Scholar
• Fatal familial insomnia: preventive treatment with doxycycline of at risk individuals. EU Clinical Trials Register, EudraCT Number: 2010-022233-28. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022233-28/IT [Last accessed 2 October 2014]
   Google Scholar
• Klyubin I, Nicoll AJ, Khalili-Shirazi A, et al. Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer’s disease Aβ synaptotoxicity. J Neurosci 2014;34:6140-5
   PubMed Web of Science ®Google Scholar
• CureFFI.org. MRC Prion Unit discusses possible clinical trial of PRN100 antibody. 2013. Available from: http://www.cureffi.org/2013/07/31/mrc-prion-unit-discusses-possible-clinical-trial-of-prn100-antibody/ [Last accessed 2 October 2014]
   Google Scholar
• Giese A, Bertsch U, Kretzschmar H, et al. New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases. US0293520A1; 2011
   Google Scholar
• Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol 2003;2:167-76
   PubMed Web of Science ®Google Scholar
• Capellari S, Strammiello R, Saverioni D, et al. Genetic Creutzfeldt-Jakob disease and fatal familial insomnia: insights into phenotypic variability and disease pathogenesis. Acta Neuropathol 2011;121:21-37
   PubMed Web of Science ®Google Scholar
• CureFFI.org. Clinical trial for doxycycline in FFI carriers will run from 2011-2022. 2012. Available from: http://www.cureffi.org/2012/01/18/clinical-trial-for-doxycycline-in-ffi-carriers-will-run-from-2011-2022/ Last accessed 2 October 2014]
   Google Scholar
• White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003;422:80-3
   PubMed Web of Science ®Google Scholar
• Freir DB, Nicoll AJ, Klyubin I, et al. Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun 2011;2:336
   PubMed Web of Science ®Google Scholar
• Collinge J, Hawke S. Treatment of prion-induced diseases by administration for anti-prion antibodies. WO050120A2; 2004
   Google Scholar
• Petsch B, Müller-Schiffmann A, Lehle A, et al. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions. J Virol 2011;85:4538-46
   PubMed Web of Science ®Google Scholar
• Klöhn PC, Farmer M, Linehan JM, et al. PrP antibodies do not trigger mouse hippocampal neuron apoptosis. Science 2012;335:52
   PubMed Web of Science ®Google Scholar
• Solforosi L, Criado JR, McGavern DB, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 2004;303:1514-16
   PubMed Web of Science ®Google Scholar
• Sonati T, Reimann RR, Falsig J, et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 2013;501:102-6
   PubMed Web of Science ®Google Scholar
• Wagner JRyazanov SLeonov A, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol 2013;125:795-813
   PubMed Web of Science ®Google Scholar
• Levin J, Schmidt F, Boehm C, et al. The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 2014;127:779-80
   PubMed Web of Science ®Google Scholar
• Max-Planck. Gesellschaft. New drug against Alzheimer’s and Parkinson’s on the way. 2014. Available from: http://www.mpg.de/7955496/anle138b_alzheimer_parkinson [Last accessed 2 October 2014]
   Google Scholar
• Thompson AG, Lowe J, Fox Z, et al. The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain 2013;136:1116-27
   PubMed Web of Science ®Google Scholar
• Tiraboschi P, Tagliavini F. Prion disease: a promising rating scale for prion disease clinical research. Nat Rev Neurol 2013;9:366-7
   Google Scholar
• Pocchiari M, Ladogana A, Graziano S, Puopolo M. Creutzfeldt-Jakob disease: hopes for therapy. Eur J Neurol 2008;15:435-6
   PubMedGoogle Scholar
• Mead S, Uphill J, Beck J, et al. Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. Hum Mol Genet 2012;21:1897-906
   PubMed Web of Science ®Google Scholar
• Sanchez-Juan P, Bishop MT, Aulchenko YS, et al. Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. Neurobiol Aging 2012;33:1487.e21-8
   Google Scholar
• Ferreira NC, Marques IA, Conceição WA, et al. Anti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approaches. PLoS One 2014;9:e84531
   PubMed Web of Science ®Google Scholar
• Thompson MJ, Borsenberger V, Louth JC, et al. Design, synthesis, and structure-activity relationship of indole-3-glyoxylamide libraries possessing highly potent activity in a cell line model of prion disease. J Med Chem 2009;52:7503-11
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S, May BC, Renslo AR, Prusiner SB. Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol 2010;84:3408-12
   PubMed Web of Science ®Google Scholar
• Berry DB, Lu D, Geva M, et al. Drug resistance confounding prion therapeutics. Proc Natl Acad Sci USA 2013;110:4160-9
   PubMed Web of Science ®Google Scholar
• Karapetyan YE, Sferrazza GF, Zhou M, et al. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents. Proc Natl Acad Sci USA 2013;110:7044-9
   PubMed Web of Science ®Google Scholar
• Aguzzi A, Nuvolone M, Zhu C. The immunobiology of prion diseases. Nat Rev Immunol 2013;13:888-902
   PubMed Web of Science ®Google Scholar
• Brazier MW, Mot AI, White AR, Collins SJ. Immunotherapeutic approaches in prion disease: progress, challenges and potential directions. Ther Deliv 2013;4:615-28
   Google Scholar
• Rovis TL, Legname G. Prion protein-specific antibodies-development, modes of action and therapeutics application. Viruses 2014;6:3719-37
   Google Scholar
• White MD, Farmer M, Mirabile I, et al. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc Natl Acad Sci USA 2008;105:10238-43
   PubMed Web of Science ®Google Scholar
• Boese AS, Majer A, Saba R, Booth SA. Small RNA drugs for prion disease: a new frontier. Expert Opin Drug Discov 2013;8:1265-84
   PubMed Web of Science ®Google Scholar
• Moreno JA, Halliday M, Molloy C, et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice. Sci Transl Med 2013;5:206ra138
   PubMed Web of Science ®Google Scholar
• Halliday M, Mallucci GR. Targeting the unfolded protein response in neurodegeneration: a new approach to therapy. Neuropharmacology 2014;76(Pt A):169-74
   PubMedGoogle Scholar
• Farlow MR, Brosch JR. Immunotherapy for Alzheimer’s disease. Neurol Clin 2013;31:869-78
   PubMed Web of Science ®Google Scholar
• Wisniewski T, Goñi F. Immunotherapy for Alzheimer’s disease. Biochem Pharmacol 2014;88:499-507
   PubMed Web of Science ®Google Scholar
• Henderson VC, Kimmelman J, Fergusson D, et al. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med 2013;10:e1001489
   Google Scholar
• Berry DB, Lu D, Geva M, et al. Drug resistance confounding prion therapeutics. Proc Natl Acad Sci USA 2013;110:4160-9
   PubMed Web of Science ®Google Scholar
• Bian J, Kang HE, Telling GC. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proc Natl Acad Sci USA 2014;111:6028-33
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S, Russo M, Renslo AR. Successes and challenges in phenotype-based lead discovery for prion diseases. J Med Chem 2014;57:6919-29
   PubMed Web of Science ®Google Scholar
• Hannaoui S, Gougerot A, Privat N, et al. Cycline efficacy on the propagation of human prions in primary cultured neurons is strain-specific. J Infect Dis 2014;209:1144-8
   PubMed Web of Science ®Google Scholar
• Bishop MT, Will RG, Manson JC. Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties. Proc Natl Acad Sci USA 2010;107:12005-10
   PubMed Web of Science ®Google Scholar
• Nonno R, Di Bari MA, Cardone F, et al. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2006;2(2):e12
   PubMed Web of Science ®Google Scholar
• Bechtel K, Geschwind MD. Ethics in prion disease. Prog Neurobiol 2013;110:29-44
   PubMed Web of Science ®Google Scholar
• Puopolo M, Pocchiari M, Petrini C. Clinical trials and methodological problems in prion diseases. Lancet Neurol 2009;8:782
   Google Scholar
• Mead S, Ranopa M, Gopalakrishnan GS, et al. PRION-1 scales analysis supports use of functional outcome measures in prion disease. Neurology 2011;77:1674-83
   Google Scholar
• Kurzrock R, Stewart DJ. Equipoise abandoned? Randomization and clinical trials. Ann Oncol 2013;24:2471-4
   Google Scholar
• Gifford F. The conflict between randomized clinical trials and the therapeutic obligation. J Med Philos 1986;11:347-66
   PubMed Web of Science ®Google Scholar
• Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987;317:141-5
   PubMed Web of Science ®Google Scholar
• Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011;364:476-80
   PubMed Web of Science ®Google Scholar
• Mitsumoto J, Dorsey ER, Beck CA, et al. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol 2009;66:184-90
   PubMed Web of Science ®Google Scholar
• Budka H, Aguzzi A, Brown P, et al. Tissue handling in suspected Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 1995;5:319-22
   PubMed Web of Science ®Google Scholar
• World Health Organization, WHO/EMC/ZDI/98.9. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation. 1998. Available from: www.who.int/csr/resources/publications/bse/whoemczdi989.pdf [Last accessed 5 October 2014]
   Google Scholar
• Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997;276:1119-22
   PubMed Web of Science ®Google Scholar